What is Mind Medicine (MindMed) Inc.'s stock symbol?

Our stock is traded on the NASDAQ under the symbol MNMD.

When was Mind Medicine (MindMed) Inc. incorporated?

We were incorporated in 2010 in British Columbia.

When did Mind Medicine (MindMed) Inc. become a public company?

We went public in February 2020 through a reverse takeover transaction and then uplisted to Nasdaq in April 2021.

Where is Mind Medicine (MindMed) Inc. located?

Mind Medicine (MindMed) Inc.
One World Trade Center
Suite 8500
New York, NY 10007
United States

When is Mind Medicine (MindMed) Inc.'s fiscal year end?

December 31st

Who is Mind Medicine (MindMed) Inc.'s transfer agent?

Computershare Investor Services
100 University Ave.
8th Floor, North Tower
Toronto, Ontario M5J2Y1
T: 1-800-564-6253 (toll free in Canada and US)
T: 514-982-7555 (international direct dial)
F: 1-888-453-0330

Who is Mind Medicine (MindMed) Inc.'s independent auditor?


How can I view documents Mind Medicine (MindMed) Inc. has filed with the Securities & Exchange Commission (SEC), including Forms 10-K and 10-Q?

You can view all SEC filings here.

How do I transfer units, warrants or stock, change the address on my account or replace a lost certificate?

You can view our Transfer Agent contact information here or further up on this FAQ page.

Does Mind Medicine (MindMed) Inc. pay dividends?

MindMed does not pay a dividend on stock, and does not foresee doing so in the immediate future. Accordingly, MindMed does not offer a DRIP (Dividend Reinvestment Program).

Does Mind Medicine (MindMed) Inc. have a direct stock purchase plan?

Currently, shares are not available for purchase directly from MindMed and we do not have a direct purchase program available.

What do I do if my address has changed?

If your shares are held in your name, you may contact Computer Investor Services. If your shares are held in Street name (by your broker), you must contact your broker to update your address.

Why is MindMed delisting from the Cboe Canada (formerly known as the NEO Exchange, Inc.)?
Shift to Nasdaq

MindMed’s Nasdaq listing provides its shareholders with sufficient liquidity, as Nasdaq accounts for approximately 95% of its trading volume when compared to the average daily trading volume of MindMed’s shares on the Cboe Canada exchange. The lower level of liquidity on Cboe Canada means there are reduced trading opportunities for shareholders. Accordingly, the Company wishes to move to having Nasdaq as its sole listing.

Administrative Costs Associated with Cboe Canada Listing

The listing of the Company on the Cboe Canada requires the Company to incur additional corporate and administrative costs, including listing fees. The Company is seeking to minimize its expenditure and would cease incurring such additional costs if it were to delist from the Cboe Canada.

Increased Focus on U.S. Institutional Investor Community

The delisting from the Cboe Canada and retention of a primary listing on Nasdaq is expected to fully leverage the Company’s increased institutional investor base and other financing options in the United States which currently has the largest and most active biotechnology capital markets ecosystem.

Location of MindMed’s Board of Directors and Employees

All of the Company's directors and employees reside outside of Canada, reflecting the Company's focus as a US-based biotechnology company.

Geographic Analysis of Shareholder Base

Based on available information, the majority of the Company’s largest shareholders are located in the United States. This reflects the shift in the Company's shareholding base toward  U.S. institutional investors.

What are the consequences of Delisting?

The main consequence of the delisting for shareholders is that, from the time the delisting takes effect on April 10, 2024 (Delisting Date), MindMed shares will no longer be quoted or traded on the Cboe Canada exchange under the ticker MMED.

Following delisting from Cboe Canada, MindMed’s shareholders can trade their common shares through their brokers on Nasdaq. As most brokers in Canada, including many discount and online brokers, have the ability to buy and sell securities listed on Nasdaq, MindMed’s Nasdaq listing will continue to provide shareholders with the same accessibility to trade the Company's common shares. Shareholders holding shares in Canadian brokerage accounts should contact their brokers to confirm how to trade MindMed’s common shares on Nasdaq.

What if my broker cannot trade on Nasdaq?

We understand that most brokers in Canada, including most discount brokers, have the ability to buy and sell securities listed on Nasdaq. If your broker is unable to trade on Nasdaq, then in order to trade your MindMed common shares you will need to open an account at a broker that is able to trade on Nasdaq.

Does delisting impact the trading of MindMed’s commons shares on Nasdaq?

No. MindMed’s common shares continue to be listed and traded on Nasdaq under the symbol: MNMD.

Once the stock is delisted on Cboe Canada will I retain the same number of shares?

Yes. The delisting will not impact the number of shares that you own.

I purchased shares in Canadian dollars. Will the new shares be valued in U.S. dollars?

Your shares will trade on Nasdaq in US dollars, and if your account trades in a Canadian trading account, the value of your shares will be converted into Canadian dollars based on the practices of your broker.